Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571429 | 1.00 | CYP1A1 (0.40) | CYP1A1CYP1B1AOC3MAPTTDP1 | |
| SCHEMBL9376529 | 0.89 | SMN1; SMN2 (0.44) | CYP1A1CYP1B1MAPTALDH1A1POLB | |
| SCHEMBL31013129 | 0.87 | ALDH1A1 (0.43) | MAPTTDP1ALDH1A1POLBKDM4E | |
| SCHEMBL881613 | 0.87 | ALDH1A1 (0.43) | MAPTTDP1ALDH1A1POLBKDM4E | |
| SCHEMBL3674074 | 0.84 | CA9 (0.50) | CYP1A1CYP1B1AOC3MAPTTDP1 | |
| SCHEMBL30701949 | 0.84 | CA9 (0.50) | CYP1A1CYP1B1AOC3MAPTTDP1 | |
| SCHEMBL1494033 | 0.83 | MAPT (0.38) | CYP1A1CYP1B1AOC3MAPTTDP1 | |
| SCHEMBL28143595 | 0.83 | CA9 (0.36) | MAPTTDP1ALDH1A1POLBKMT2A | |
| SCHEMBL27814462 | 0.81 | KDM4E (0.42) | MAPTTDP1ALDH1A1POLBCYP19A1 | |
| SCHEMBL3745577 | 0.80 | TSHR (0.44) | MAPTTDP1ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104262114-A | Preparation method of 2,3,4-trimethoxy iodobenzene | UNIV HENAN SCIENCE & TECH | 2015-01-07 | — | — | CN | claimed |
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | SPERMATECH AS (NO) | 2023-08-24 | — | — | US | disclosed |
| CN-104945389-B | A kind of mountain ketone colour contamination ketone compounds and its preparation method and application | 中国科学院上海药物研究所 | 2018-04-13 | — | — | CN | disclosed |
| CN-104262229-B | Preparation method of 2-phenyl substituted-3-benzoyl substituted indole | 广东颐正达医药科技有限公司 | 2016-10-05 | — | — | CN | disclosed |
| CN-104230682-B | A kind of method preparing alkoxyl iodobenzene | 河南科技大学 | 2016-09-07 | — | — | CN | disclosed |
| CN-104945389-A | Xanthone cross-color ketone compound as well as preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2015-09-30 | — | — | CN | disclosed |
| CN-103172480-B | Method for preparing iodo aromatic hydrocarbon | UNIV HENAN SCIENCE & TECH | 2015-01-21 | — | — | CN | disclosed |
| CN-104262114-A | Preparation method of 2,3,4-trimethoxy iodobenzene | UNIV HENAN SCIENCE & TECH | 2015-01-07 | — | — | CN | disclosed |
| CN-104262114-A | Preparation method of 2,3,4-trimethoxy iodobenzene | UNIV HENAN SCIENCE & TECH | 2015-01-07 | — | — | CN | disclosed |
| CN-104262114-A | Preparation method of 2,3,4-trimethoxy iodobenzene | UNIV HENAN SCIENCE & TECH | 2015-01-07 | — | — | CN | disclosed |
| EP-1513515-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003096982-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0584222-B1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | NR5A1, NR1I3, NR5A2 | CYP1A1 189/4885CYP1B1 295/4885AOC3 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.